Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Results from MajesTEC-1: health-related quality of life with teclistamab in patients with R/R MM

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, shares some updates from the MajesTEC-1 trial (NCT04557098) investigating the use of teclistamab, a bispecific T-cell engager (BiTE), for the treatment of patients with relapsed/refractory (R/R) multiple myeloma. Dr Popat highlights the improved response rate and progression-free survival (PFS) observed in patients, and further discusses the improved quality of life reported in patient questionnaires. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.